Skip to content
DataLookout
Menu

NCT07928700

Phase 2 Study of pH Gastrilex™ (Enteric-Coated Amorphous Calcium Carbonate Capsules) in Moderate-to-Severe Crohn's Disease

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change From Baseline in Crohn's Disease Activity Index (CDAI)
Timeframe: Baseline and 12 weeks

Secondary (10)

Percentage of participants achieving clinical remission Clinical Remission
Percentage of participants achieving clinical response
Change From Baseline in Stool Frequency
Change From Baseline in Abdominal Pain Score
Endoscopic Response
Show 5 moreShow less
Change From Baseline in Quality of Life (SIBDQ)
Long-Term Maintenance of Clinical Remission
Long-Term Maintenance of Clinical Response
C-Reactive Protein (CRP) Normalization
Fecal Calprotectin ≤250 µg/g

Arms and interventions

PH Gastrilex™Experimental

PH Gastrilex™ (Amorphous Calcium Carbonate)

Placebo groupPlacebo comparator

Placebo Followed by PH Gastrilex™ (Amorphous Calcium Carbonate)

Drugs: PH Gastrilex, Placebo Comparator

Sites

1 site in 1 country

  • Soroka University Medical CenterBeersheba, South, Israel